Jeudi 24 juin 2010 - Novel targeting drugs & Radiotherapy


8h30	Cérémonie d’ouverture
9h00	Conférence : Conférence d’introduction : Gillies McKenna, Directeur du Département de Radio-Oncologie, Gray Institut, Université d’Oxford, Royaume-Uni. “Tumor Conditioning : A Novel Use of Signal Transduction Inhibitors."

9h45	Séance plénière : Mécanismes intra-cellulaires de radiorésistance tumorale
9h45	Philip J. Tofilon, Departement d’Oncologie Interdisciplinaire, Drug Discovery Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA "In vitro and in vivo radioresponse of glioblastoma stem-like cells"
10h30 - 11h15	Hans-Peter Rodemann, Division de Radiobiologie moléculaire et de recherche sur l’environnement, Département de radio-oncologie, Université de Tuebingen, Allemagne "ErbR receptor signaling and control of DNA repair"

11h15	Pause café

11h45 - 13h15	Communications orales

• Sebastien Guihard : The Amyloid ?? Precursor Protein-Binding Protein 1 (APP-BP1) gene expression level modulates the radiosensitivity of Human head and neck squamous cell carcinoma cell lines through the neddylation pathway and is a promising therapeutic target.
• Conchita Vens : Exploiting base excision repair deficiencies for tumor-targeted radiosensitization.
• Marcel Verheij SHIP-1 down-regulation determines resistance to alkyl-lysophospholipid-, DNA damage- and FAS ligand-induced apoptosis in mouse lymphoma cells.
• Thierry Muanza : Apoptosis in Breast Cancer Cells Undergoing a Combined Administration of Novel Targeted Molecules and Radiation.
• Cyril Buhler : A multiscale comparison of the distribution of short dsDNA (DBAIT) complexed with polyethylenimine (PEI) or conjugated to cholesterol to sensitize tumor to radiotherapy.


13h15	Déjeuner

14h - 15h	Symposium Roche Alfredo Zurlo, MD. Medical Director - Oncology, Roche France. "Roche’s Oncology Pipeline." Marc Chamberlain, MD. University of Washington - Seattle Cancer Care Alliance, Seattle, USA : "Angiogenesis inhibition and radiation therapy in glioma" Christopher Willett, MD. Duke University Medical Center, Durham, USA : "Angiogenesis inhibition and radiation therapy in GI cancers”
15h	Séance plénière : Angiogenèse
15h	Dai Fukumura, Chef de projet du laboratoire E Steele , Harvard, USA. "Targeting tumor microvasculature and microenvironment".
15h45	Oriol Casanovas, Laboratoire de Recherche Translationnelle, Institut Catalan d’oncologie - IDIBELL, Barcelone, Espagne “Evasive resistance to antiangiogenic therapies : from mechanisms to clinical relevance”

16h30	Pause café

16h45 - 18h15	Communications orales

• Anthony Brade : Preliminary results : a phase I study of Sorafenib and palliative radiation in patients with malignancy in the thorax, abdomen or pelvis.
• François Paris : P38-mediated endothelial cell death after ionizing radiation is under the control of reactive reaction species, ceramide generation and membrane remodelling.
• Severine Planel : FGFR1-induced radioresistance of Panc02 pancreatic tumor cells is decreased by SSR128129 treatment in vitro and in vivo.
• Alexandra Benouaich-Amiel : Bevacizumab and irinotecan in recurrent high grade glioma : a retrospective monocentric study.
• Christine Toulas : Targeting FGFR-1 pathways by the antagonist SSR128129E overcomes the radioresistance of human glioma in vitro and in vivo.


20h15	Soirée de Gala, Restaurant le 19